Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irrever...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/10/2807 |
| _version_ | 1797498878377852928 |
|---|---|
| author | Ewa Robak Tadeusz Robak |
| author_facet | Ewa Robak Tadeusz Robak |
| author_sort | Ewa Robak |
| collection | DOAJ |
| description | The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irreversible inhibitors, covalent reversible inhibitors, and non-covalent reversible inhibitors. Ibrutinib is the first covalent, irreversible BTK inhibitor approved in 2013 as a breakthrough therapy for chronic lymphocytic leukemia patients. Subsequently, two other covalent, irreversible, second-generation BTKis, acalabrutinib and zanubrutinib, have been developed for lymphoid malignancies to reduce the ibrutinib-mediated adverse effects. More recently, irreversible and reversible BTKis have been under development for immune-mediated diseases, including autoimmune hemolytic anemia, immune thrombocytopenia, multiple sclerosis, pemphigus vulgaris, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s disease, and chronic spontaneous urticaria, among others. This review article summarizes the preclinical and clinical evidence supporting the role of BTKis in various autoimmune, allergic, and inflammatory conditions. |
| first_indexed | 2024-03-10T03:39:35Z |
| format | Article |
| id | doaj.art-660458e867994bea863e578679bc12f8 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T03:39:35Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-660458e867994bea863e578679bc12f82023-11-23T11:35:07ZengMDPI AGJournal of Clinical Medicine2077-03832022-05-011110280710.3390/jcm11102807Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and PerspectivesEwa Robak0Tadeusz Robak1Department of Dermatology, Medical University of Lodz, 90-647 Lodz, PolandDepartment of Hematology, Medical University of Lodz, 93-510 Lodz, PolandThe use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irreversible inhibitors, covalent reversible inhibitors, and non-covalent reversible inhibitors. Ibrutinib is the first covalent, irreversible BTK inhibitor approved in 2013 as a breakthrough therapy for chronic lymphocytic leukemia patients. Subsequently, two other covalent, irreversible, second-generation BTKis, acalabrutinib and zanubrutinib, have been developed for lymphoid malignancies to reduce the ibrutinib-mediated adverse effects. More recently, irreversible and reversible BTKis have been under development for immune-mediated diseases, including autoimmune hemolytic anemia, immune thrombocytopenia, multiple sclerosis, pemphigus vulgaris, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s disease, and chronic spontaneous urticaria, among others. This review article summarizes the preclinical and clinical evidence supporting the role of BTKis in various autoimmune, allergic, and inflammatory conditions.https://www.mdpi.com/2077-0383/11/10/2807AIHAatopic dermatitisBTK inhibitorchronic spontaneous urticariaIgG4-related diseaseITP |
| spellingShingle | Ewa Robak Tadeusz Robak Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives Journal of Clinical Medicine AIHA atopic dermatitis BTK inhibitor chronic spontaneous urticaria IgG4-related disease ITP |
| title | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
| title_full | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
| title_fullStr | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
| title_full_unstemmed | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
| title_short | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
| title_sort | bruton s kinase inhibitors for the treatment of immunological diseases current status and perspectives |
| topic | AIHA atopic dermatitis BTK inhibitor chronic spontaneous urticaria IgG4-related disease ITP |
| url | https://www.mdpi.com/2077-0383/11/10/2807 |
| work_keys_str_mv | AT ewarobak brutonskinaseinhibitorsforthetreatmentofimmunologicaldiseasescurrentstatusandperspectives AT tadeuszrobak brutonskinaseinhibitorsforthetreatmentofimmunologicaldiseasescurrentstatusandperspectives |